ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
8 (USD) • At close March 12, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 1.032 | 0.966 | 0.897 | 0.97 | 1 | 0.9 | 0.9 |
| Gross Profit
| 0 | -1.032 | -0.966 | -0.897 | -0.97 | -1 | -0.9 | -0.9 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 114.072 | 85.172 | 61.68 | 56.858 | 35.921 | 22.844 | 19.026 | 19.126 |
| General & Administrative Expenses
| 28.823 | 25.608 | 25.087 | 22.013 | 13.422 | 5.725 | 3.345 | 3.415 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.9 |
| SG&A
| 28.823 | 25.608 | 25.087 | 22.013 | 13.422 | 5.725 | 3.345 | 2.515 |
| Other Expenses
| 0 | 0 | 5 | 0.015 | 0.177 | 0.289 | 0.233 | 0 |
| Operating Expenses
| 142.895 | 110.78 | 86.767 | 78.871 | 49.343 | 28.569 | 22.371 | 21.641 |
| Operating Income
| -142.895 | -110.78 | -91.767 | -78.871 | -74.186 | -28.569 | -22.371 | -22.541 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 15.048 | 10.083 | 2.645 | 0.156 | 0.483 | 1.686 | 1.008 | 0.512 |
| Income Before Tax
| -127.847 | -100.697 | -89.122 | -78.715 | -73.703 | -26.883 | -21.363 | -22.029 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 2.355 | -1.038 | 23.567 | -1.397 | -1.008 | 0 |
| Net Income
| -127.847 | -100.697 | -91.477 | -77.677 | -97.27 | -25.486 | -21.363 | -22.029 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.83 | -1.96 | -2.31 | -2.05 | -4.43 | -0.85 | -1.12 | -0.74 |
| EPS Diluted
| -1.83 | -1.96 | -2.31 | -2.05 | -4.43 | -0.85 | -1.12 | -0.74 |
| EBITDA
| -142.895 | -109.748 | -91.767 | -77.974 | -74.186 | -27.541 | -20.463 | -21.129 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |